Immunogenicity of the 3rd COVID-19 vaccine dose in Thai healthcare workers at Bamrasnaradura Infectious Diseases Institute
Active, not recruiting
- Conditions
- Healthcare workers who received two doses of SinovacCOVID-19 VaccineSARS-CoV-2AntibodyHealthcare WorkersAstraZenecaPfizer
- Registration Number
- TCTR20211005001
- Lead Sponsor
- ational Research Council of Thailand (NRCT)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 170
Inclusion Criteria
1. Age 18 years or more
2. Healthcare workers at Bamrasnaradura Infectious Diseases Institute
3. Received 2nd dose of Sinovac at least 21 days before
4. Eligible for ChAdOx1/AZD1222 COVID-19 vaccine
5. Informed consent for participation
Exclusion Criteria
Allergy to a component of ChAdOx1/AZD1222 COVID-19 Vaccine
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SARS-CoV-2 antibodies Before vaccination, 4 weeks post vaccination, 12 weeks post vaccination IgG (ELISA), Neutralizaing antibody (NeutraLISA)
- Secondary Outcome Measures
Name Time Method Cellular immunity Before vaccination, 4 weeks post vaccination, 12 weeks post vaccination T cell (Fluorospot), Memory B cell (Fluorospot),COVID-19 infection rate Before vaccination, 1 day post vaccination, 7 days post vaccination, 4 weeks post vaccination, 12 weeks post vaccination Symptom Assessment and confirmed with Real-time RT-PCR if suspected,Adverse events Before vaccination, 1 day post vaccination, 7 days post vaccination, 4 weeks post vaccination, 12 weeks post vaccination Patient report outcomes
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the enhanced antibody response after a third dose of Sinovac in Thai healthcare workers?
How does a third dose of Sinovac compare to AstraZeneca and Pfizer vaccines in boosting immunity against SARS-CoV-2 variants?
Which biomarkers correlate with immunogenicity outcomes following a third dose of Sinovac in healthcare workers with prior exposure?
What are the potential adverse events associated with a third dose of Sinovac in healthcare workers, and how do they compare to other vaccines?
Are there combination vaccine strategies involving Sinovac that improve long-term protection against SARS-CoV-2 in high-risk populations?